## **IREDELL HEALTH SYSTEM**

Naloxone Dosing Guidelines	
Approved by:	Last Revised/Reviewed Date:
Vijay Nagpal, MD, Emergency Medicine	
Laura Rollings, PharmD, BCPS, BCGP	
Dept of Emergency Medicine	Date: 02/2025
Critical Care Committee	Date: 03/2025
P&T Committee	Date: 04/2025

**Purpose:** To provide guidance on the appropriate administration of naloxone for opioid overdose. **Policy:** Criteria for naloxone administration:

- Respiratory Rate (RR) of 10 or below **OR**
- RR trending downward significantly from normal baseline
- **AND** at least one of the following:
  - $\circ$  Signs of inadequate ventilation (O<sub>2</sub> saturation < 90%, hypotensive)
  - Somnolent, difficult to arouse or unarousable (with no other apparent cause)
  - Pinpoint pupils (patients with history of cataract surgery may have impaired pupil response)

## **Procedure:**

A. For non-life threatening dosing (opioid tolerant\* patients and/or non-apneic beathing):

- 1. Administer naloxone 0.4 mg (400 mcg) in 10 mL NS for a final concentration 0.04 mg/mL every 2 5 minutes
- 2. Repeat dose until improvement in RR and mental status sustained
- 3. \*Opioid tolerant is defined as 60 mg morphine daily or equivalent, for at least 5 days
- B. For Life threatening emergency or overdose (Imminent risk of death) very low RR and/or apneic breathing:
  - 1. Administer naloxone 0.4 mg (400 mcg), up to 2 mg IV Push
  - 2. May repeat every 2-3 minutes, if needed

## C. Naloxone Infusion: standard concentration 4 mg / NS 100 mL (0.04 mg/mL)

<b>Starting Dose:</b> Start dose consistent with 2/3	<b>Titration Guidelines:</b> Titrate to respiratory rate > 10 and	
of naloxone bolus doses needed to sustain	improvement in mental status for 4 hours.	
normal respirations	Increase rate by 25% for any of the following:	
	1. RR of $\leq 7$	
	2. Resp interval of $\geq 15$ seconds	
Example:	3. $PaO_2 < 60 \text{ mmHg with } PaCO_2 > 46 \text{ mmHg}$	
40 mcg bolus doses x $3 = 120$ mcg (0.12 mg) Initial rate = 80 mcg/hr (0.12 mg/hr).	4. PaCO <sub>2</sub> > 55 mmHg or arterial blood pH > 7.3 without metabolic acidosis	
	5. Inadequate response to verbal commands	
	Decrease infusion rate by 25% for any of the following: 1. Increase of self reported pain intensity	
	2. Acute sympathomimetic (nervousness, severe headache,	
	2. Actic sympationinetic (hervousness, severe headache, anxiety, vertigo, nausea, vomiting) or psychotomimetic symptoms (confusion, hallucinations) under adequate hemodynamic and metabolic treatment	
	<ol> <li>Stable condition lasting 4 hours without any symptoms of overdose</li> </ol>	

## D. Naloxone Infusion Monitoring

- 1. Patients requiring a continuous naloxone infusion require continuous cardiac monitoring
- 2. Vital signs (RR, BP, HR, pulse oximetry, level of sedation, pain) shall be documented every 15 minutes during infusion and 4 hours after infusion has been discontinued.
- 3. Reassess patient 30 minutes after any rate change.
- 4. Notify provider for signs/symptoms of withdrawal (nausea, vomiting, sweating, tachycardia, tremor and tachypnoea) or incidence of inadequate response to naloxone.
- 5. If respiratory depression occurs during infusion, bolus with  $\frac{1}{2}$  the initial bolus dose every 3 5 minutes until symptoms improve, then increase infusion by  $\frac{1}{2}$  the rate.

INITIAL EFFECTIVE DATE: 05/2025 DATES REVISIONS EFFECTIVE: DATES REVIEWED (no changes):